Answers are grounded in this paper and cite their sources.
The I-SPY 2 breast cancer trials assess activity of new agents by adaptive randomization, applying criteria for success on a surrogate end point to predict success in confirmatory trials. Innovative designs may speed progress and eliminate waste in drug development.
No takes yet. Share an insight, caveat, or question.
Harrington et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: